BioCentury
ARTICLE | Company News

Celgene, Hayman Capital Management cancer news

May 18, 2015 7:00 AM UTC

Hedge fund manager Kyle Bass filed a second inter partes review (IPR) challenging a patent covering Celgene’s Revlimid lenalidomide. An entity associated with Bass, filed the IPR with the U.S. Patent and Trademark Office challenging U.S. Patent No. 5,635,517. The petition challenges on the grounds of obviousness the patent’s claims covering methods of administering thalidomide analogs to reduce tumor necrosis factor (TNF) alpha in mammals and the chemical structure of certain thalidomide analogs.

The ‘517 patent is set to expire in 2019 and is one of 24 Orange Book-listed patents covering Revlimid. Last month, Bass challenged another Revlimid patent, U.S. Patent No. 6,045,501, which claims methods for preventing fetal exposure to teratogenic drugs. The last Orange Book-listed patent for Revlimid expires in 2028 (see BioCentury, April 27). ...